Lung Cancer: Targets and Therapy

Dr Sai-Hong Ignatius Ou

Dr Ou

University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA

Professor Sai-Hong Ignatius Ou is currently the Health Science Clinical Professor of Medicine in the Department of Medicine, Division of Hematology Oncology at the University of California Irvine School of Medicine. Dr. Ou received his MD and PhD degrees from the University of Texas Southwestern Medical School and completed internship and residency in internal medicine at Duke University Medical Center. Dr. Ou completed his hematology-oncology fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School. Dr. Ou has served an an institutional review committee member for more than 10 years at the University of California Irvine School of Medicine and has been involved in mentoring hematology-oncology fellows and other young investigators globally.

Dr. Ou is one of the eight original phase 1 investigators of crizotinib, and is the senior and corresponding author of the US phase 1 dose escalation of alectinib in the US and participated in the clinical trials of lorlatinib. Dr. Ou has published close to 130 peer-reviewed articles including publication in New Journal of Medicine, The Lancet Oncology, Journal of Clinical Oncology, JAMA Oncology, and Cancer Discovery. Dr. Ou is on the scientific advisor board of TP Therapeutics which is developing the fourth generation ALK/ROS1/NTRK inhibitor that can overcome solvent front mutations. His major research interests are in targeted therapy in lung cancer and other solid malignancies that harbors actionable driver mutations in particular receptor tyrosine kinase fusions and the strategies to overcome resistance to tyrosine kinase inhibitors. Dr. Ou serves on the editorial board of Annals of Oncology, Clinical Lung Cancer, and Translational Lung Cancer research and have been ad hoc reviewer for New England Journal of Medicine, The Lancet, The Lancet Oncology and Journal of Clinical Oncology among other journals. Dr. Ou is on the scientific committee for metastatic lung cancer for the American Society of Clinical Oncology annual meeting from 2016-2018.

Professor Fengying Wu

Professor Wu

Department of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China

Dr. Fengying Wu is an associate professor at the Medical School of Tongji University's Department of Oncology, currently based at the Shanghai Pulmonary Hospital. She completed her postgraduate studies at Fudan University, and received her MD and PhD degrees from Tongji University. Dr. Wu completed her residency and fellowship in oncology at the Shanghai Pulmonary Hospital. She has been an associate professor at Tongji University since 2018 and has mentored postgraduate students and oncology fellows for several years.

Dr. Wu is involved in several phase II and phase III clinical trials for lung cancer, including the Camel, Camel-sq, Alesia, and Keynote-033 studies. She has also conducted several translational studies, with a focus on single-cell analysis in advanced lung cancer.

Dr. Wu has published over 25 articles in respected medical journals such as The Lancet Respiratory Medicine, Journal of Clinical Oncology, Nature Communications, Oncogenes, and Cancer Communications. Currently, she serves as the office director of the Lung Cancer Special Committee of the Chinese Primary Health Care Foundation, Vice Chairman of the Youth Committee of the Cancer Branch of the Shanghai Medical Association, and a member of the Standing Committee of Lung Cancer of the Chinese Elderly Health Care Association. Dr. Wu has won several awards, including the Mentorship Award of the IASLC and the First Prize of the Science and Technology Award of the Chinese Anti-Cancer Association (ranked 10th).